CS1-SPECIFIC SINGLE-DOMAIN ANTIBODIES LABELED WITH ACTINIUM-225 PROLONG SURVIVAL AND INCREASE CD8+ T CELLS AND PD-L1 EXPRESSION IN MULTIPLE MYELOMA

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche.Despite significant therapeutic advances, MM remains incurable for the majority of patients.Targeted radionuclide therapy (TRNT) has emerged as a promising treatment option to eradicate residual cancer Adjustable Base ce

read more


Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

Matteo Bassetti,1,2 Mari Ariyasu,3 Bruce Binkowitz,4 Tsutae Den Nagata,3 Roger M Echols,5 Yuko Matsunaga,4 Glucosamine Chondroitin Formulas Kiichiro Toyoizumi,4 Yohei Doi6 1Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy; 2Department of Health Sciences, University o

read more

Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance

Abstract Immunocompromised (IC) patients face significant challenges in managing COVID-19 due to their heightened susceptibility to severe illness, persistent infections, and the potential development of drug resistance.Studies indicate that IC patients, particularly those with hematologic malignancies (HM), hematopoietic stem cell transplants (HSC

read more